Effects of L-carnitine supplementation on oxidative stress and antioxidant enzymes activities in patients with coronary artery disease: a randomized, placebo-controlled trial

Bor-Jen Lee, Jun-Shuo Lin, Yi-Chin Lin, Ping-Ting Lin, Bor-Jen Lee, Jun-Shuo Lin, Yi-Chin Lin, Ping-Ting Lin

Abstract

Background: Cardiovascular disease is the leading cause of death worldwide. Higher oxidative stress may contribute to the pathogenesis of coronary artery disease (CAD). The purpose of this study was to investigate the effect of L-carnitine (LC, 1000 mg/d) on the markers of oxidative stress and antioxidant enzymes activities in CAD patients.

Methods: We enrolled 47 CAD patients in the study. The CAD patients were identified by cardiac catheterization as having at least 50% stenosis of one major coronary artery. The subjects were randomly assigned to the placebo (n = 24) and LC (n = 23) groups. The intervention was administered for 12 weeks. The levels of serum LC, plasma malondialdehyde (MDA), and erythrocyte antioxidant enzymes activities [catalase (CAT), superoxide dismutase (SOD), glutathione peroxidase (GPx)] were measured before and after intervention.

Results: Thirty-nine subjects completed the study (placebo, n = 19; LC, n = 20). After 12 weeks of LC supplementation, the level of MDA was significantly reduced (2.0 ± 0.3 to 1.8 ± 0.3 μmol/L, P = 0.02) and the level of LC (33.6 ± 13.6 to 40.0 ± 12.0 μmol/L, P = 0.04) and antioxidant enzymes activities [CAT (12.7 ± 5.5 to 13.1 ± 5.8 U/mg of protein, P = 0.02), SOD (14.8 ± 2.9 to 20.7 ± 5.8 U/mg of protein, P < 0.01), and GPx (20.3 ± 3.4 to 23.0 ± 3.1 U/mg of protein, P = 0.01)] were significantly increased. The level of LC was significantly positively correlated with the antioxidant enzymes activities (CAT, β = 0.87, P = 0.02; SOD, β = 0.72, P < 0.01).

Conclusion: LC supplementation at a dose of 1000 mg/d was associated with a significant reduction in oxidative stress and an increase in antioxidant enzymes activities in CAD patients. CAD patients might benefit from using LC supplements to increase their anti-oxidation capacity.

Trial registration: Clinical Trials.gov Identifier: NCT01819701.

Figures

Figure 1
Figure 1
Flow diagram. F, female; LC, L-carnitine; M, male.
Figure 2
Figure 2
Levels of L-carnitine, oxidative stress, and antioxidant enzymes activities after supplementation. Data are means ± SD. □ week 0, ■ week 12. *Values were significantly different after intervention within the group. a, bValues with different superscripts were significantly different between the two groups. CAT, catalase; GPx, glutathione peroxidase; LC, L-carnitine; MDA, malondialdehyde; SOD, superoxide dismutase.

References

    1. Braunwald E. Shattuck lecture-cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. N Engl J Med. 1997;337:1360–1369. doi: 10.1056/NEJM199711063371906.
    1. Harrison D, Griendling KG, Landmesser U, Hornig B, Drexlar H. Role of oxidative stress in atherosclerosis. Am J Cardio. 2003;91:7–11. doi: 10.1016/S0002-9149(02)03144-2.
    1. Gaby AR. Nutritional treatments for acute myocardial infarction. Altern Med Rev. 2010;15:113–123.
    1. Kendler BS. Carnitine: an overview of its role in preventive medicine. Prev Med. 1986;15:373–390. doi: 10.1016/0091-7435(86)90005-8.
    1. Flanagan JL, Simmons PA, Vehige J, Willcox MD, Garrett Q. Role of carnitine in disease. Nutr Metab. 2010;7:30. doi: 10.1186/1743-7075-7-30.
    1. Bremer J. Carnitine metabolism and function. Physiol Rev. 1983;63:1420–1479.
    1. Sener G, Paskaloğlu K, Satiroglu H, Alican I, Kaçmaz A, Sakarcan A. L-carnitine ameliorates oxidative damage due to chronic renal failure in rats. J Cardiovasc Pharmacol. 2004;43:698–705. doi: 10.1097/00005344-200405000-00013.
    1. Gülçin I. Antioxidant and antiradical activities of L-carnitine. Life Sci. 2006;78:803–811. doi: 10.1016/j.lfs.2005.05.103.
    1. Kolodziejczyk J, Saluk-Juszczak J, Wachowicz B. L-Carnitine protects plasma components against oxidative alterations. Nutrition. 2011;27:693–699. doi: 10.1016/j.nut.2010.06.009.
    1. Cao Y, Qu HJ, Li P, Wang CB, Wang LX, Han ZW. Single dose administration of L-carnitine improve antioxidant activities in human subjects. Tohoku J Exp Med. 2011;224:209–213. doi: 10.1620/tjem.224.209.
    1. Singh RB, Niaz MA, Agarwal P, Beegum R, Rastogi SS, Sachan DS. A randomised, double-blind, placebo-controlled trial of L-carnitine in suspected acute myocardial infarction. Postgrad Med J. 1996;72:45–50. doi: 10.1136/pgmj.72.843.45.
    1. Singh RB, Aslam M. L-carnitine administration in coronary artery disease and cardiomyopathy. J Assoc Physicians India. 1998;46:801–805.
    1. Lango R, Smolenski RT, Narkiewicz M, Suchorzewska J, Lysiak-Szydlowska W. Influence of L-carnitine and its derivatives on myocardial metabolism and function in ischemic heart disease and during cardiopulmonary bypass. Cardiovasc Res. 2001;51:21–29. doi: 10.1016/S0008-6363(01)00313-3.
    1. Walter MF, Jacob RF, Jeffers B, Ghadanfar MM, Preston GM, Buch J, Mason RP. PREVENT study. Serum levels of thiobarbituric acid reactive substances predict cardiovascular events in patients with stable coronary artery disease: a longitudinal analysis of the PREVENT study. J Am Coll Cardiol. 2004;44:1996–2002. doi: 10.1016/j.jacc.2004.08.029.
    1. Ho E, Karimi Galougahi K, Liu CC, Bhindi R, Figtree GA. Biological markers of oxidative stress: Applications to cardiovascular research and practice. Redox Biol. 2013;1:483–491. doi: 10.1016/j.redox.2013.07.006.
    1. Botsoglou NA. Rapid, sensitive, and specific thiobarbituric acid method for measuring lipid peroxidation in animal tissue, food and feedstuff samples. J Agric Food Chem. 1994;42:1931–1937. doi: 10.1021/jf00045a019.
    1. Paglia D, Valentine W. Studies on the qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med. 1967;70:159–169.
    1. Marklund S, Marklund G. Involvement of superoxide anion radical in autoxidation of pyrogallol and a convenient assay for superoxide dismutase. Eur J Biochem. 1974;47:469–474. doi: 10.1111/j.1432-1033.1974.tb03714.x.
    1. Aebi H. Catalase in vitro. Methods Enzymol. 1984;105:121–126.
    1. Richards RS, Roberts TK, Dunstan RH, McGregor NR, Butt HL. Erythrocyte antioxidant systems protect cultured endothelial cells against oxidant damage. Biochem Mol Biol Int. 1998;46:857–865.
    1. de Sotomayor MA, Mingorance C, Rodriguez-Rodriguez R, Marhuenda E, Herrera MD. L-carnitine and its propionate: improvement of endothelial function in SHR through superoxide dismutase-dependent mechanisms. Free Radic Res. 2007;41:884–891. doi: 10.1080/10715760701416467.
    1. Ribas GS, Vargas CR, Wajner M. L-carnitine supplementation as a potential antioxidant therapy for inherited neurometabolic disorders. Gene. 2014;533:469–476. doi: 10.1016/j.gene.2013.10.017.
    1. Lysiak W, Lilly K, DiLisa F, Toth PP, Bieber LL. Quantitation of the effect of L-carnitine on the levels of acid-soluble short-chain acyl-CoA and CoASH in rat heart and liver mitochondria. J Biol Chem. 1988;263:1151–1156.
    1. Broderick TL, Quinney HA, Lopaschuk GD. Carnitine stimulation of glucose oxidation in the fatty acid perfused isolated working rat heart. J Biol Chem. 1992;267:3758–3763.
    1. Mingorance C, Rodríguez-Rodríguez R, Justo ML, Alvarez de Sotomayor M, Herrera MD. Critical update for the clinical use of L-carnitine analogs in cardiometabolic disorders. Vasc Health Risk Manag. 2011;7:169–176.
    1. Botham KM, Mayes PA. In: Harper’s Illustrated Biochemistry. Chapter 15. 29. Murray RK, Bender DA, Botham KM, Kennelly PJ, Rodwell VW, Weil PA, editor. New York: McGraw-Hill Companies; 2012. Lipids of physiologic significance.
    1. Dhalla NS, Temsah RM, Netticadan T. Role of oxidative stress in cardiovascular diseases. J Hypertens. 2000;18:655–673. doi: 10.1097/00004872-200018060-00002.
    1. Harrison D, Griendling KK, Landmesser U, Hornig B, Drexler H. Role ofoxidative stress in atherosclerosis. Am J Cardiol. 2003;91:7A–11A. doi: 10.1016/S0002-9149(02)03144-2.
    1. Glass CK, Witztum JL. Atherosclerosis: the road ahead. Cell. 2001;104:503–516. doi: 10.1016/S0092-8674(01)00238-0.
    1. Schnabel R, Stefan B. Oxidative stress in cardiovascular disease. Successful translation from bench to beside? Circulation. 2007;116:1338–1340. doi: 10.1161/CIRCULATIONAHA.107.728394.
    1. Guby AR. Nutrition treatments for acute myocardial infarction. Altern Med Rev. 2010;15:113–123.
    1. Johri AM, Heyland DK, Hétu MF, Crawford B, Spence JD. Carnitine therapy for the treatment of metabolic syndrome and cardiovascular disease: Evidence and controversies. Nutr Metab Cardiovasc Dis. 2014. in press.
    1. Spagnoli LG, Corsi M, Villaschi S, Palmieri G, Maccari F. Myocardial carnitine deficiency in acute myocardial infarction. Lancet. 1982;1:1419–1420.
    1. Suzuki Y, Masumura Y, Kobayashi A, Yamazaki N, Harada Y, Osawa M. Myocardial carnitine deficiency in chronic heart failure. Lancet. 1982;1:116.
    1. McCarty MF. L-carnitine consumption, its metabolism by intestinal microbiota, and cardiovascular health. Mayo Clin Proc. 2013;88:786–789. doi: 10.1016/j.mayocp.2013.06.004.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren